Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
162.10 | 2,694 Cr | 21.41 | 0.42 | 0.00 | 2.14 | 3.12 | 1.07 | ||
346.00 | 2,606 Cr | 8.28 | 1.07 | 0.00 | 5.98 | 6.30 | 8.29 | ||
994.40 | 2,433 Cr | 25.24 | 3.14 | 2.54 | 13.75 | 17.93 | 10.43 | ||
37.98 | 2,356 Cr | 21.10 | 1.97 | 0.47 | 6.31 | 8.14 | 5.77 | ||
183.10 | 2,336 Cr | -172.74 | 1.96 | 0.42 | 0.85 | 4.28 | -0.55 | ||
358.30 | 2,226 Cr | -298.58 | 2.69 | 0.00 | -5.71 | -5.58 | -0.65 | ||
469.95 | 2,150 Cr | 86.55 | 4.58 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Median: 7 Co. | — | 346.00 | 2,356 Cr | 21.10 | 1.97 | 0.00 | 2.14 | 4.28 | 1.07 |
Morepen Laboratories Ltd (MOREPENLAB) is currently trading at 43.27 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Morepen Laboratories is an India-based integrated pharmaceutical and medical-device company producing APIs, formulations and point-of-care medical devices with a product mix split roughly 62% pharma (API+Rx) and 38% medical devices, and manufacturing sites including a USFDA-approved facility and a hi-tech pharma complex in Himachal Pradesh. Financial momentum in Q3 FY26 shows consolidated gross revenue of Rs. 488 crores and standalone gross revenue of Rs. 462 crores with strong sequential improvement: consolidated PAT rose 83% year-on-quarter (Q2 to Q3) and standalone PAT increased 77%, reflecting operating leverage and non-recurring income components in the quarter. Medical devices are the primary growth engine: device revenue grew 44% year-on-year in Q3 and 18% over 9M, driven by glucometers which now represent 76% of device revenue, cumulative sales of 16.85 million meters and 2.33 billion strips, indicating scale in consumables and recurring revenue streams. Pharma/API revenue is stagnating: total pharma revenue declined 3% over 9M and API revenue fell 5% year-on-year, with APIs concentrated in a few molecules (Atorva, Lorata+Des, Monte) and a higher share of sales in Europe and India, while the U.S. share remains low at 3% of quarterly revenue. Geographic mix is shifting toward domestic demand, with India rising to 64.1% of Q3 revenue and the U.S. contribution contracting; this concentration amplifies domestic opportunity but also raises exposure to India-specific pricing, distribution and regulatory dynamics that management must navigate.
Over the past 52 weeks, Morepen Laboratories Ltd has traded between a low of ₹33.44 and a high of ₹70.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Morepen Laboratories Ltd has a market capitalization of approximately 2,355.65. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Morepen Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.10 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,355.65 Cr, Morepen Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Morepen Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Morepen Laboratories Ltd is 21.10. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It means the USFDA inspection concluded with zero observations recorded in Form 483, indicating no deficiencies were cited during the inspection.
Morepen Laboratories' share price surged by up to 16% after the company announced it had secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate worth approximately ₹825 crore from a major global pharmaceutical company.
The most significant announcement is the 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay to boost domestic biopharma manufacturing, which directly benefits API producers like Morepen Labs.
Regulatory Clearance
Morepen Laboratories’ Masulkhana (Himachal Pradesh) API facility was cleared by the USFDA on 17 Apr 2026 with zero observations (NIL Form 483), the fourth consecutive NIL 483 in eight years, reinforcing regulatory compliance and export credibility.
USFDA Clearance
Morepen Laboratories' Masulakhanna API facility cleared the USFDA inspection on 17-Apr-2026 with no observations (NIL Form 483), its fourth consecutive NIL 483, reinforcing regulatory compliance and global supply credentials.
Morepen Laboratories is an India-based integrated pharmaceutical and medical-device company producing APIs, formulations and point-of-care medical devices with a product mix split roughly 62% pharma (API+Rx) and 38% medical devices, and manufacturing sites including a USFDA-approved facility and a hi-tech pharma complex in Himachal Pradesh.
Financial momentum in Q3 FY26 shows consolidated gross revenue of Rs. 488 crores and standalone gross revenue of Rs. 462 crores with strong sequential improvement: consolidated PAT rose 83% year-on-quarter (Q2 to Q3) and standalone PAT increased 77%, reflecting operating leverage and non-recurring income components in the quarter.
Medical devices are the primary growth engine: device revenue grew 44% year-on-year in Q3 and 18% over 9M, driven by glucometers which now represent 76% of device revenue, cumulative sales of 16.85 million meters and 2.33 billion strips, indicating scale in consumables and recurring revenue streams.
Pharma/API revenue is stagnating: total pharma revenue declined 3% over 9M and API revenue fell 5% year-on-year, with APIs concentrated in a few molecules (Atorva, Lorata+Des, Monte) and a higher share of sales in Europe and India, while the U.S. share remains low at 3% of quarterly revenue.
Geographic mix is shifting toward domestic demand, with India rising to 64.1% of Q3 revenue and the U.S. contribution contracting; this concentration amplifies domestic opportunity but also raises exposure to India-specific pricing, distribution and regulatory dynamics that management must navigate.
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,356 Cr
High Risk
21.1
32.3
125.1
2.0
70.40
33.44
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
8
Neutral
2
Bullish
4
Bearish
10
Neutral
2
Bullish
34
Bearish
2
Neutral
0
Bullish
30
